Denali Therapeutics (DNLI) Current Assets (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Current Assets of $1.0 billion for Q1 2026, up 16.4% year-over-year from $878.6 million in Q1 2025, and up 13.56% quarter-over-quarter from $900.7 million in Q4 2025.
Denali Therapeutics (DNLI) Current Assets (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Current Assets for 10 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 16.4% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 16.4% YoY), while the FY2025 annual figure was $900.7 million, up 4.19% from the prior year.
- Current Assets advanced to $1.0 billion in Q1 2026 per DNLI's latest filing, from $900.7 million in the prior quarter.
- Across five years, Current Assets topped out at $1.4 billion in Q4 2022 and bottomed at $864.4 million in Q4 2024.
- Historically, Current Assets has averaged $1.0 billion across 5 years, with a median of $988.4 million in 2022.
- On a YoY basis, Current Assets climbed as much as 52.95% in 2022 and fell as far as 30.96% in 2022.
- Denali Therapeutics' Current Assets stood at $1.4 billion in 2022, then dropped by 22.46% to $1.1 billion in 2023, then decreased by 18.77% to $864.4 million in 2024, then grew by 4.19% to $900.7 million in 2025, then grew by 13.56% to $1.0 billion in 2026.
- Business Quant data shows DNLI's Current Assets at $1.0 billion in Q1 2026, $900.7 million in Q4 2025, and $882.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 753.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 753.93 Mn |
| Mar 31, 2026 | 1.02 Bn |
| Dec 31, 2025 | 900.66 Mn |
| Sep 30, 2025 | 882.60 Mn |
| Jun 30, 2025 | 934.71 Mn |
| Mar 31, 2025 | 878.64 Mn |
| Dec 31, 2024 | 864.44 Mn |
| Sep 30, 2024 | 868.84 Mn |
| Jun 30, 2024 | 928.38 Mn |
| Mar 31, 2024 | 973.58 Mn |
| Dec 31, 2023 | 1.06 Bn |
| Sep 30, 2023 | 1.14 Bn |
| Jun 30, 2023 | 1.22 Bn |
| Mar 31, 2023 | 1.33 Bn |
| Dec 31, 2022 | 1.37 Bn |
| Sep 30, 2022 | 1.14 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 988.44 Mn |
| Dec 31, 2021 | 897.23 Mn |
| Sep 30, 2021 | 1.06 Bn |